COM.TO - Cardiome Pharma Corp.

Toronto - Toronto Delayed Price. Currency in CAD
1.92
+0.07 (+3.78%)
At close: 3:53PM EST
Stock chart is not supported by your current browser
Previous Close1.85
Open1.86
Bid1.88 x 0
Ask1.95 x 0
Day's Range1.86 - 1.99
52 Week Range1.64 - 6.06
Volume22,270
Avg. Volume22,330
Market Cap66.481M
Beta-2.43
PE Ratio (TTM)N/A
EPS (TTM)-0.84
Earnings DateMay 12, 2017 - May 15, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.45
  • PR Newswire5 days ago

    Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia

    VANCOUVER, Dec. 12, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that its affiliate Correvio has entered into an exclusive license and distribution agreement with ZAO Firma Euroservice that will advance Aggrastat® (tirofiban hydrochloride) toward commercialization in Russia. Aggrastat is indicated for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) and is currently marketed in over 60 countries worldwide. Under the terms of the license agreement, ZAO will be responsible for obtaining regulatory approvals for Aggrastat from Russia's Ministry of Health, then executing the commercial launch and subsequent sale and marketing of Aggrastat in the territory.

  • CNW Group5 days ago

    Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia

    VANCOUVER, Dec. 12, 2017 /CNW/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that its affiliate Correvio has entered into an exclusive license and distribution agreement with ZAO Firma Euroservice that will advance Aggrastat® (tirofiban hydrochloride) toward commercialization in Russia. Aggrastat is indicated for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) and is currently marketed in over 60 countries worldwide. Under the terms of the license agreement, ZAO will be responsible for obtaining regulatory approvals for Aggrastat from Russia's Ministry of Health, then executing the commercial launch and subsequent sale and marketing of Aggrastat in the territory.

  • Baystreet6 days ago

    Stocks in play: Cardiome Pharma Corp.

    Announced a plenary sponsored symposium at the 2017 National Outpatient Parenteral Antimicrobial Therapy ...

  • CNW Group6 days ago

    Cardiome Highlights Partner SteadyMed's Agreement With FDA On Pathway To Trevyent NDA Resubmission

    VANCOUVER, Dec. 11, 2017 /CNW/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today highlighted that its partner SteadyMed Therapeutics (NASDAQ:STDY - News) has reached agreement with the U.S. Food and Drug Administration (FDA) on the work necessary to resubmit the New Drug Application (NDA) for Trevyent® for the treatment of pulmonary arterial hypertension (PAH). Based on written feedback received from the FDA, SteadyMed indicated that is not required to conduct any clinical trials to prove the safety or efficacy of Trevyent and that the FDA has agreed that certain in vitro design verification (DV) tests on the final to-be-marketed Trevyent product, supported by pharmacokinetic modelling and process validation, should be adequate for the resubmission and acceptance of the 505(b)(2) NDA.

  • PR Newswire6 days ago

    Cardiome Highlights Partner SteadyMed's Agreement With FDA On Pathway To Trevyent NDA Resubmission

    VANCOUVER, Dec. 11, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today highlighted that its partner SteadyMed Therapeutics (STDY) has reached agreement with the U.S. Food and Drug Administration (FDA) on the work necessary to resubmit the New Drug Application (NDA) for Trevyent® for the treatment of pulmonary arterial hypertension (PAH). Based on written feedback received from the FDA, SteadyMed indicated that is not required to conduct any clinical trials to prove the safety or efficacy of Trevyent and that the FDA has agreed that certain in vitro design verification (DV) tests on the final to-be-marketed Trevyent product, supported by pharmacokinetic modelling and process validation, should be adequate for the resubmission and acceptance of the 505(b)(2) NDA.

  • PR Newswire6 days ago

    Cardiome Announces Xydalba™ Treatment And Patient Experience Presentations At The 2017 National Opat Conference

    VANCOUVER, Dec. 11, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced a plenary sponsored symposium at the 2017 National Outpatient Parenteral Antimicrobial Therapy (OPAT) Conference, hosted by the British Society for Antimicrobial Chemotherapy, taking place December 11-12, 2017 in Birmingham, UK. The Company-sponsored plenary symposium, titled, "Managing serious skin infections within the changing NHS, time for a rethink?" will feature presentations by three physician experts describing treatment and patient experience with Cardiome's Xydalba™ (dalbavancin hydrochloride), the first and only 30-minute, one-dose treatment option for acute bacterial skin and skin structure infections. Cardiome currently markets Xydalba in France, Germany, the UK, the Republic of Ireland, Belgium, Finland and Sweden.

  • CNW Group6 days ago

    Cardiome Announces Xydalba™ Treatment And Patient Experience Presentations At The 2017 National Opat Conference

    VANCOUVER, Dec. 11, 2017 /CNW/ - Cardiome Pharma Corp. (NASDAQ:CRME / TSX:COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced a plenary sponsored symposium at the 2017 National Outpatient Parenteral Antimicrobial Therapy (OPAT) Conference, hosted by the British Society for Antimicrobial Chemotherapy, taking place December 11-12, 2017 in Birmingham, UK. The Company-sponsored plenary symposium, titled, "Managing serious skin infections within the changing NHS, time for a rethink?" will feature presentations by three physician experts describing treatment and patient experience with Cardiome's Xydalba™ (dalbavancin hydrochloride), the first and only 30-minute, one-dose treatment option for acute bacterial skin and skin structure infections. Cardiome currently markets Xydalba in France, Germany, the UK, the Republic of Ireland, Belgium, Finland and Sweden.

  • ACCESSWIRE19 days ago

    Toronto Exchanges Stock Review Healthcare stocks Concordia International, ProMetic Life Sciences, Theratechnologies, and Cardiome Pharma

    LONDON, UK / ACCESSWIRE / November 28, 2017 / Active-Investors' free stock reports for this morning include these Toronto Exchanges' equities from the Biotechnology industry: Concordia International (TSX: ...

  • PR Newswire27 days ago

    Cardiome to Present at the 29th Annual Piper Jaffray Healthcare Conference

    VANCOUVER, Nov. 20, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that Mr. Justin Renz, Chief Financial Officer of Cardiome, will present at the 29th Annual Piper Jaffray Healthcare Conference. The presentation will take place at the Lotte New York Palace on Tuesday, November 28, 2017 at 2:30 p.m. EDT.

  • CNW Group27 days ago

    Cardiome to Present at the 29th Annual Piper Jaffray Healthcare Conference

    NASDAQ: CRME TSX: COM VANCOUVER , Nov. 20, 2017 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected ...

  • CNW Grouplast month

    Cardiome Reports Third Quarter 2017 Financial Results

    NASDAQ: CRME TSX: COM Management to Host Conference Call and Webcast Today, November 14, 2017 at 4:30 p.m. ET ( 1:30 p.m. PT ) VANCOUVER , Nov. 14, 2017 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: ...

  • PR Newswirelast month

    Cardiome Reports Third Quarter 2017 Financial Results

    NASDAQ: CRME TSX: COM Management to Host Conference Call and Webcast Today, November 14, 2017 at 4:30 p.m. ET ( 1:30 p.m. PT ) VANCOUVER , Nov. 14, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME ...

  • ACCESSWIRElast month

    Today’s Research Reports on Cardiome Pharma, IntelliPharmaCeutics International, Nuvo Pharmaceuticals and Oncolytics Biotech Inc.

    NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register ...

  • PR Newswirelast month

    Cardiome To Hold Third Quarter 2017 Financial Results Conference Call On November 14

    VANCOUVER, Nov. 7, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected hospital drugs, today announced that it will report financial results for the third quarter ended September 30, 2017 on Tuesday, November 14, 2017. Cardiome will hold a conference call and webcast at 4:30 p.m. Eastern (1:30 p.m. Pacific) on that day to discuss the results. To access the conference call, please dial 416-764-8688 or 888-390-0546 and use conference ID 66802456.

  • CNW Grouplast month

    Cardiome To Hold Third Quarter 2017 Financial Results Conference Call On November 14

    NASDAQ: CRME TSX: COM VANCOUVER , Nov. 7, 2017 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing patent-protected ...

  • PR Newswirelast month

    Cardiome Announces Expansion of Global Geographic Footprint for Brinavess®

    VANCOUVER, Nov. 2, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the expansion of its geographic presence for Brinavess (vernakalant hydrochloride, IV) into the two new key territories of South Africa and Pakistan.  Following the recent receipt of authorization from South Africa's Department of Health, Brinavess was launched in South Africa by Cardiome's partner Aspen Medical, preparing for the first sale of the product on the African continent. Cardiome is eligible to receive payments from Aspen Medical based on pre-specified annual commercial goals.  Aspen Medical, who also markets Aggrastat® in South Africa, is a wholly-owned subsidiary of Aspen Pharmacare (a division of the Aspen Group), the largest pharmaceutical company in Africa.  In addition to this commercial launch, a Cardiome affiliate, Correvio International Sàrl, entered into an exclusive license and distribution agreement with ATCO Laboratories Limited that will advance Brinavess toward commercialization in Pakistan.  Under the terms of the license agreement, ATCO will be responsible for obtaining, at its own cost, regulatory and pricing approvals for Brinavess from the Drug Regulatory Authority of Pakistan, then executing the commercial launch and subsequent sale and marketing of Brinavess in the territory.

  • CNW Grouplast month

    Cardiome Announces Expansion of Global Geographic Footprint for Brinavess®

    VANCOUVER, Nov. 2, 2017 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the expansion of its geographic presence for Brinavess (vernakalant hydrochloride, IV) into the two new key territories of South Africa and Pakistan.  Following the recent receipt of authorization from South Africa's Department of Health, Brinavess was launched in South Africa by Cardiome's partner Aspen Medical, preparing for the first sale of the product on the African continent. Cardiome is eligible to receive payments from Aspen Medical based on pre-specified annual commercial goals.  Aspen Medical, who also markets Aggrastat® in South Africa, is a wholly-owned subsidiary of Aspen Pharmacare (a division of the Aspen Group), the largest pharmaceutical company in Africa.  In addition to this commercial launch, a Cardiome affiliate, Correvio International Sàrl, entered into an exclusive license and distribution agreement with ATCO Laboratories Limited that will advance Brinavess toward commercialization in Pakistan.  Under the terms of the license agreement, ATCO will be responsible for obtaining, at its own cost, regulatory and pricing approvals for Brinavess from the Drug Regulatory Authority of Pakistan, then executing the commercial launch and subsequent sale and marketing of Brinavess in the territory.